Current Smoking and Response to Cholinesterase Inhibitor Therapy in Alzheimer’s Disease

Publisher： Karger

E-ISSN： 1421-9824|19|1|11-14

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.19, Iss.1, 2004-12, pp. : 11-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cholinesterase Inhibitor Therapies and Neuropsychiatric Manifestations of Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 17, Iss. 1-2, 2003-12 ,pp. : 100-108

Karger

Access to resources Recommend Favorite

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 2, 2002-07 ,pp. : 84-89

Karger

Access to resources Recommend Favorite

Cholinesterase Inhibitor Affects the Amyloid Precursor Protein Isoforms in Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 19, Iss. 5-6, 2005-04 ,pp. : 345-348

Karger

Access to resources Recommend Favorite

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer’s Disease and Other Dementias

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 2, Iss. 1, 2012-11 ,pp. : 546-572

Karger

Access to resources Recommend Favorite

Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 40, Iss. 5-6, 2015-0 ,pp. : 243-255

Karger

Access to resources Recommend Favorite